Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
EDSA
Upturn stock ratingUpturn stock rating

Edesa Biotech Inc (EDSA)

Upturn stock ratingUpturn stock rating
$2.26
Last Close (24-hour delay)
Profit since last BUY-3.21%
upturn advisory
SELL
SELL since 4 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: EDSA (1-star) is a SELL. SELL since 4 days. Profits (-3.21%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $10.33

1 Year Target Price $10.33

Analysts Price Target For last 52 week
$10.33 Target price
52w Low $1.55
Current$2.26
52w High $5

Analysis of Past Performance

Type Stock
Historic Profit -40.71%
Avg. Invested days 33
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 15.89M USD
Price to earnings Ratio -
1Y Target Price 10.33
Price to earnings Ratio -
1Y Target Price 10.33
Volume (30-day avg) 1
Beta 0.27
52 Weeks Range 1.55 - 5.00
Updated Date 08/15/2025
52 Weeks Range 1.55 - 5.00
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.24

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Earnings Date

Report Date 2025-08-08
When -
Estimate -0.5
Actual -0.25

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -40.22%
Return on Equity (TTM) -69.64%

Valuation

Trailing PE -
Forward PE 0.17
Enterprise Value 14869782
Price to Sales(TTM) 120477.93
Enterprise Value 14869782
Price to Sales(TTM) 120477.93
Enterprise Value to Revenue 128525.38
Enterprise Value to EBITDA -1.25
Shares Outstanding 7029750
Shares Floating 3595042
Shares Outstanding 7029750
Shares Floating 3595042
Percent Insiders 28.55
Percent Institutions 30.1

ai summary icon Upturn AI SWOT

Edesa Biotech Inc

stock logo

Company Overview

overview logo History and Background

Edesa Biotech Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative treatments for inflammatory and immune-related diseases. Founded in 2011, the company has pursued a strategy of identifying and developing promising clinical-stage assets. Key milestones include securing patents, completing clinical trials, and seeking regulatory approvals.

business area logo Core Business Areas

  • Pharmaceutical Development: Focuses on the development of pharmaceutical products targeting inflammatory and immune-related diseases. This includes clinical trials and regulatory submissions.

leadership logo Leadership and Structure

The company is led by a management team with experience in drug development and commercialization. The organizational structure includes departments for research and development, clinical operations, and regulatory affairs.

Top Products and Market Share

overview logo Key Offerings

  • EB05 (sebudiazone): A monoclonal antibody being developed for Acute Respiratory Distress Syndrome (ARDS). Currently in clinical development. Market share is currently 0 as no sales have been reported. Competitors include companies developing ARDS treatments, such as those focusing on ventilator management and other pharmacological interventions. Approval is not yet granted by the FDA.
  • Cryptococcus neoformans Diagnostic Test: Diagnostic test is under development. Market share is currently 0 as no sales have been reported. Competitors include companies such as Thermo Fisher Scientific (TMO).

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant competition. Demand is driven by aging populations, increasing prevalence of chronic diseases, and advances in medical technology.

Positioning

Edesa Biotech Inc. is positioning itself as a developer of niche therapies for inflammatory and immune-related diseases, often focusing on areas with unmet medical needs. Competitive advantages could include novel mechanisms of action and successful clinical trial outcomes.

Total Addressable Market (TAM)

TAM is difficult to estimate due to the specific indications and clinical stage of its products. However, the global market for ARDS treatments is estimated to be in the billions of dollars. The company's positioning within this TAM depends on successful clinical trials and regulatory approvals.

Upturn SWOT Analysis

Strengths

  • Proprietary technology and intellectual property
  • Experienced management team
  • Focus on unmet medical needs
  • Potential for breakthrough therapies

Weaknesses

  • Limited financial resources
  • Dependence on clinical trial outcomes
  • High regulatory risk
  • Lack of commercialized products

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion into new therapeutic areas
  • Successful clinical trial results
  • Regulatory approvals and commercialization

Threats

  • Competition from larger pharmaceutical companies
  • Failure to achieve clinical trial endpoints
  • Regulatory setbacks
  • Changes in healthcare policies

Competitors and Market Share

competitor logo Key Competitors

Competitive Landscape

Edesa Biotech Inc. faces competition from larger pharmaceutical companies with more resources. Its competitive advantage lies in its focus on niche therapies and innovative approaches.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is characterized by expansion of the pipeline and progression of clinical trials.

Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization. Analyst estimates vary widely due to the uncertainty of drug development.

Recent Initiatives: Recent initiatives include advancing clinical trials for EB05 and seeking partnerships to fund further development.

Summary

Edesa Biotech Inc. is a high-risk, high-reward biopharmaceutical company focused on developing treatments for inflammatory and immune-related diseases. While the company has promising clinical-stage assets, it faces significant challenges in securing funding, achieving clinical trial success, and obtaining regulatory approvals. Successful development and commercialization of its pipeline could lead to substantial growth, but failure in any of these areas could negatively impact the company. Edesa needs to look out for competition and changes in healthcare policies.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Press releases
  • Third-party market research reports

Disclaimers:

The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on your own due diligence and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Edesa Biotech Inc

Exchange NASDAQ
Headquaters Markham, ON, Canada
IPO Launch date 2015-11-05
CEO, Company Secretary & Director Dr. Pardeep Nijhawan FRCPC, M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 16
Full time employees 16

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.